PDCD1 and cancer: Therefore, higher levels of circulatory HMGB1 prior to anti-PD-1/PD-L1 antibody therapy may be associated with acceleration of cancer immunity, thereby improving the efficacy of anti-PD-1/PD-L1 antibody monotherapy.